Choose a language and wait for the translated text.
Shots:
AriBio has reported data from the P-III (POLARIS-AD) trial of oral AR1001 (30mg) in early Alzheimer’s disease, with the 1EP of change in CDR-SB at wk. 52 evaluated in two prespecified populations (Overall & Monotherapy)
The trial met its primary efficacy objective in the Monotherapy population (n=604; pts not on an AChE inhibitor or memantine at baseline), with a CDR-SB treatment difference of −0.44 vs PBO (p=0.0266; 31% slowing of clinical decline); in the Overall population (n=1,535) the difference was −0.11 (p=0.4015) and did not reach statistical significance
AR1001 was generally well tolerated (TEAEs 69.0% vs 66.4%); secondary measures trended in favor of AR1001, with a nominally significant MMSE finding in the Monotherapy population; AriBio plans to discuss the findings with the US FDA
Ref: GlobeNewswire | Image: AriBio | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post AriBio Reports P-III (POLARIS-AD) Data of Oral AR1001 for Early Alzheimer’s Disease appeared first on PharmaShots.